BIOMAT Database Logo BIOMAT Database Logo

Protection of OK-432, a Streptococcus pyogenes preparation, against lethal infection of mice with herpes simplex virus. 1989

Y Harada, and E Kurokawa, and H Endo, and T Kimura, and M Saito, and Y Sugawara, and H Irie, and K Ito, and M Fujii, and Y Shimizu
Research Laboratories, Chugai Pharmaceutical Co., Ltd., Tokyo.

We have studied the protective effect of OK-432, a biological response modifier (BRM) of Streptococcus pyogenes origin, on the lethal infection of mice with herpes simplex virus (HSV)-1. A single intraperitoneal (i.p.) injection of more than 10 micrograms of OK-432, when given at least two days before the infection, gave a marked effect yielding nearly 100% protection against ordinarily lethal infection. The protection was independent of the amount of infected virus inoculated. When given after the infection, the agent even at the maximal dose (100 micrograms), produced only a marginal effect. A single i.p. administration of OK-432 augmented the natural killer (NK) activity of peritoneal exudate cells and spleen mononuclear cells in mice 2 to 3 days after injection of OK-432, coinciding with the times when it induced a survival effect on HSV-infection. Treating OK-432-treated mice with a combination of an anti-macrophage agent, silica, and an anti-NK cell agent, anti-asialo GM1 serum, before infection diminished the antiviral effect of OK-432. The OK-432 protection against HSV infection was also markedly diminished in athymic nude mice. Thus, the protective effect of OK-432 on lethal HSV infection seems to be based on the activation of NK cells, macrophages, and T lymphocytes.

UI MeSH Term Description Entries
D007274 Injections, Intraperitoneal Forceful administration into the peritoneal cavity of liquid medication, nutrient, or other fluid through a hollow needle piercing the abdominal wall. Intraperitoneal Injections,Injection, Intraperitoneal,Intraperitoneal Injection
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D008262 Macrophage Activation The process of altering the morphology and functional activity of macrophages so that they become avidly phagocytic. It is initiated by lymphokines, such as the macrophage activation factor (MAF) and the macrophage migration-inhibitory factor (MMIF), immune complexes, C3b, and various peptides, polysaccharides, and immunologic adjuvants. Activation, Macrophage,Activations, Macrophage,Macrophage Activations
D008297 Male Males
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D008809 Mice, Inbred C3H An inbred strain of mouse that is used as a general purpose strain in a wide variety of RESEARCH areas including CANCER; INFECTIOUS DISEASES; sensorineural, and cardiovascular biology research. Mice, C3H,Mouse, C3H,Mouse, Inbred C3H,C3H Mice,C3H Mice, Inbred,C3H Mouse,C3H Mouse, Inbred,Inbred C3H Mice,Inbred C3H Mouse
D008819 Mice, Nude Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses. Athymic Mice,Mice, Athymic,Nude Mice,Mouse, Athymic,Mouse, Nude,Athymic Mouse,Nude Mouse
D010844 Picibanil A lyophilized preparation of a low-virulence strain (SU) of Streptococcus pyogenes (S. hemolyticus), inactivated by heating with penicillin G. It has been proposed as a noncytotoxic antineoplastic agent because of its immune system-stimulating activity. NSC-B116209,OK-432,Picibanyl,Streptococcal OK-432,Streptococcal Preparation OK-432,NSC B116209,NSCB116209,OK 432,OK432,Streptococcal OK 432,Streptococcal OK432,Streptococcal Preparation OK 432,Streptococcal Preparation OK432
D004306 Dose-Response Relationship, Immunologic A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell. Immunologic Dose-Response Relationship,Relationship, Immunologic Dose-Response,Dose Response Relationship, Immunologic,Dose-Response Relationships, Immunologic,Immunologic Dose Response Relationship,Immunologic Dose-Response Relationships,Relationship, Immunologic Dose Response,Relationships, Immunologic Dose-Response
D006561 Herpes Simplex A group of acute infections caused by herpes simplex virus type 1 or type 2 that is characterized by the development of one or more small fluid-filled vesicles with a raised erythematous base on the skin or mucous membrane. It occurs as a primary infection or recurs due to a reactivation of a latent infection. (Dorland, 27th ed.) Herpes Simplex Virus Infection

Related Publications

Y Harada, and E Kurokawa, and H Endo, and T Kimura, and M Saito, and Y Sugawara, and H Irie, and K Ito, and M Fujii, and Y Shimizu
Expression of herpes simplex virus 1 glycoprotein B by a recombinant vaccinia virus and protection of mice against lethal herpes simplex virus 1 infection.
August 1987, Proceedings of the National Academy of Sciences of the United States of America,
Y Harada, and E Kurokawa, and H Endo, and T Kimura, and M Saito, and Y Sugawara, and H Irie, and K Ito, and M Fujii, and Y Shimizu
Expression of herpes simplex virus 1 glycoprotein B in human cells and protection of mice against lethal herpes simplex virus 1 infection.
January 1989, Advances in experimental medicine and biology,
Y Harada, and E Kurokawa, and H Endo, and T Kimura, and M Saito, and Y Sugawara, and H Irie, and K Ito, and M Fujii, and Y Shimizu
Neuropathogenicity of herpes simplex virus in mice: protection against lethal encephalitis by co-infection with a non-encephalitogenic strain.
September 1983, The Journal of general virology,
Y Harada, and E Kurokawa, and H Endo, and T Kimura, and M Saito, and Y Sugawara, and H Irie, and K Ito, and M Fujii, and Y Shimizu
The cytotoxic action of OK-432 from Streptococcus pyogenes.
October 1990, Medical hypotheses,
Y Harada, and E Kurokawa, and H Endo, and T Kimura, and M Saito, and Y Sugawara, and H Irie, and K Ito, and M Fujii, and Y Shimizu
Protection against herpes simplex virus infection in mice by Corynebacterium parvum.
April 1977, Infection and immunity,
Y Harada, and E Kurokawa, and H Endo, and T Kimura, and M Saito, and Y Sugawara, and H Irie, and K Ito, and M Fujii, and Y Shimizu
Streptococcus pyogenes preparation OK-432: immunoprophylactic and immunotherapeutic effects on the incidence of spontaneous leukemia in AKR mice.
March 1976, Journal of the National Cancer Institute,
Y Harada, and E Kurokawa, and H Endo, and T Kimura, and M Saito, and Y Sugawara, and H Irie, and K Ito, and M Fujii, and Y Shimizu
Induction of interferon-gamma in mouse spleen cells by OK-432, a preparation of Streptococcus pyogenes.
March 1982, Cellular immunology,
Y Harada, and E Kurokawa, and H Endo, and T Kimura, and M Saito, and Y Sugawara, and H Irie, and K Ito, and M Fujii, and Y Shimizu
Control of endotoxin shock by the dried preparation of low virulent Streptococcus pyogenes OK-432.
September 1998, Cellular immunology,
Y Harada, and E Kurokawa, and H Endo, and T Kimura, and M Saito, and Y Sugawara, and H Irie, and K Ito, and M Fujii, and Y Shimizu
Immunogenicity of subviral herpes simplex virus preparations: protection of mice against intraperitoneal infection with live virus.
December 1980, Acta virologica,
Y Harada, and E Kurokawa, and H Endo, and T Kimura, and M Saito, and Y Sugawara, and H Irie, and K Ito, and M Fujii, and Y Shimizu
Antitumor activity of a Streptococcus pyogenes preparation (OK-432). II. Analysis of the cytotoxic lymphocytes induced by OK-432 injection into tumor-bearing F344 rats.
November 1987, Journal of the National Cancer Institute,
Copied contents to your clipboard!